Literature DB >> 26092313

How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease?

Darryl Bannon1, Anne M Landau, Doris J Doudet.   

Abstract

The combination of novel imaging techniques with the use of small animal models of disease is often used in attempt to understand disease mechanisms, design potential clinical biomarkers and therapeutic interventions, and develop novel methods with translatability to human clinical conditions. However, it is clear that most animal models are deficient when compared to the complexity of human diseases: they cannot sufficiently replicate all the features of multisystem disorders. Furthermore, some practical differences may affect the use or interpretation of animal imaging to model human conditions such as the use of anesthesia, various species differences, and limitations of methodological tools. Nevertheless, imaging animal models allows us to dissect, in interpretable bits, the effects of one system upon another, the consequences of variable neuronal losses or overactive systems, the results of experimental treatments, and we can develop and validate new methods. In this review, we focus on imaging modalities that are easily used in both human subjects and animal models such as positron emission and magnetic resonance imaging and discuss aging and Parkinson's disease as prototypical examples of preclinical imaging studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26092313     DOI: 10.1007/s11910-015-0571-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  74 in total

1.  Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism.

Authors:  Yilong Ma; Shichun Peng; Phoebe G Spetsieris; Vesna Sossi; David Eidelberg; Doris J Doudet
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-30       Impact factor: 6.200

2.  Dopamine transporter imaging in the aged rat: a [¹²³I]FP-CIT SPECT study.

Authors:  Aida Niñerola-Baizán; Santiago Rojas; Núria Roé-Vellvé; Francisco Lomeña; Domènec Ros; Javier Pavía
Journal:  Nucl Med Biol       Date:  2015-01-09       Impact factor: 2.408

3.  Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.

Authors:  Adjmal Nahimi; Mette Høltzermann; Anne M Landau; Mette Simonsen; Steen Jakobsen; Aage Kristian Olsen Alstrup; Kim Vang; Arne Møller; Gregers Wegener; Albert Gjedde; Doris J Doudet
Journal:  J Neurochem       Date:  2012-01-23       Impact factor: 5.372

4.  Distribution of the 5-HT(1A) receptor antagonist [ (18)F]FPWAY in blood and brain of the rat with and without isoflurane anesthesia.

Authors:  Joji Tokugawa; Laura Ravasi; Toshiyuki Nakayama; Lixin Lang; Kathleen C Schmidt; Jurgen Seidel; Michael V Green; Louis Sokoloff; William C Eckelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-22       Impact factor: 9.236

5.  In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD.

Authors:  Vesna Sossi; James E Holden; Geoffrey J Topping; Marie-Laure Camborde; Rich A Kornelsen; Siobhan E McCormick; Jennifer Greene; Andrei R Studenov; Thomas J Ruth; Doris J Doudet
Journal:  J Cereb Blood Flow Metab       Date:  2007-01-24       Impact factor: 6.200

6.  Pharmacological challenge and synaptic response - assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET).

Authors:  Susanne Nikolaus; Rolf Larisch; Henning Vosberg; Markus Beu; Andreas Wirrwar; Christina Antke; Konstantin Kley; Maria Angelica De Souza Silva; Joseph P Huston; Hans-Wilhelm Müller
Journal:  Rev Neurosci       Date:  2011-11-22       Impact factor: 4.353

7.  PET imaging of cholinergic deficits in rats using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV).

Authors:  Maxime Parent; Marc-Andre Bedard; Antonio Aliaga; Jean-Paul Soucy; Evelyne Landry St-Pierre; Marilyn Cyr; Alexey Kostikov; Esther Schirrmacher; Gassan Massarweh; Pedro Rosa-Neto
Journal:  Neuroimage       Date:  2012-04-25       Impact factor: 6.556

8.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine.

Authors:  S D Tabbal; J W Mink; J A V Antenor; J L Carl; S M Moerlein; J S Perlmutter
Journal:  Neuroscience       Date:  2006-06-12       Impact factor: 3.590

9.  Molecular imaging of conscious, unrestrained mice with AwakeSPECT.

Authors:  Justin S Baba; Christopher J Endres; Catherine A Foss; Sridhar Nimmagadda; Hyeyun Jung; James S Goddard; Seungjoon Lee; John McKisson; Mark F Smith; Alexander V Stolin; Andrew G Weisenberger; Martin G Pomper
Journal:  J Nucl Med       Date:  2013-03-27       Impact factor: 10.057

10.  In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals.

Authors:  Eduardo Rigon Zimmer; Antoine Leuzy; Venkat Bhat; Serge Gauthier; Pedro Rosa-Neto
Journal:  Transl Neurodegener       Date:  2014-03-15       Impact factor: 8.014

View more
  3 in total

Review 1.  The use of nonhuman primate models to understand processes in Parkinson's disease.

Authors:  Javier Blesa; Inés Trigo-Damas; Natalia López-González Del Rey; José A Obeso
Journal:  J Neural Transm (Vienna)       Date:  2017-03-29       Impact factor: 3.575

Review 2.  Biomarker Research in Parkinson's Disease Using Metabolite Profiling.

Authors:  Jesper F Havelund; Niels H H Heegaard; Nils J K Færgeman; Jan Bert Gramsbergen
Journal:  Metabolites       Date:  2017-08-11

3.  Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.

Authors:  Michel Modo; William R Crum; Madeline Gerwig; Anthony C Vernon; Priya Patel; Michael J Jackson; Sarah Rose; Peter Jenner; Mahmoud M Iravani
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.